| VVOS 0.196 -12.85% | CLGN 0.3879 8.35% | PCG 13.27 -20.06% | GPRO 0.8762 46.06% | AIM 0.226 -12.54% | NVDA 220.78 1.48% | TSLL 9.97 11.02% | CNH 11.83 1.28% | RDHL 0.9 36.16% | NVD 3.93 -2.96% | NU 14.55 1.75% | BITO 10.63 1.72% | COOT 0.5928 28.87% | AAL 13.43 -1.54% | FNGR 0.223 -43.97% | INTC 89.51 0.04% | SOAR 0.2325 7.19% | NCRA 2.83 49.74% | SPCX 143.69 1.55% | TSLA 367.95 5.51% | PATH 18.67 2.87% | LGCL 0.0351 -9.77% | ABEV 2.87 0.35% | AEHL 6.49 83.33% | PFE 28.46 1.79% | AMZN 259.77 -2.50% | NIO 4.24 -2.97% | NOK 10.14 -0.69% | BAC 61.94 -0.61% | SNAP 5.55 2.21% | KEEL 3.15 -2.17% | IBIT 44.67 1.75% | TQQQ 71.92 0.10% | WETO 5.48 -4.20% | BMNR 25.32 6.39% | AAPL 316.85 -0.89% | PURR 12.25 5.51% | F 13.94 0.43% | WBUY 0.9 8.43% | ROIV 34.64 -0.20% | IREN 37.115 4.70% | CDE 20.78 -1.66% | SPY 767.05 -0.30% | IONQ 39.31 0.28% | T 25.88 -0.50% | HYG 79.81 0.09% | SOFI 17.88 -1.00% | TLT 82.52 -0.43% | SLB 60.1 4.83% | PLUG 2.16 -1.37%

Azenta, Inc. (NASDAQ: AZTA) Overview: A Leader in Life Sciences Solutions

Azenta, Inc. (NASDAQ: AZTA) is a prominent figure in the life sciences sector, specializing in sample exploration and management solutions. The company, formerly known as Brooks Automation, Inc., underwent a rebranding in December 2021 to better reflect its focused vision and services. Azenta operates through two main segments: Life Sciences Products and Life Sciences Services, catering to a diverse clientele including pharmaceutical and biotechnology companies, biorepositories, and research institutes.

The financial outlook for Azenta remains positive, with a stable consensus price target of $38 over recent months. However, Evercore ISI projects a more optimistic future for the company, setting a price target of $62. This optimism is supported by Azenta's strong financial performance, highlighted by a 36% increase in third-quarter earnings per share (EPS). With the fiscal fourth quarter and full year 2025 earnings report on the horizon, investors and analysts alike are keen to see if Azenta can maintain its growth trajectory.

Key Insights:

- Azenta, Inc. operates in the life sciences industry, offering automated cold sample management systems and comprehensive sample management programs.

- The consensus price target for Azenta has remained stable at $38, with Evercore ISI setting a more optimistic target of $62.

- Azenta reported a 36% increase in third-quarter EPS, indicating strong operational performance and supporting the higher price target set by Evercore ISI.

Azenta's upcoming fiscal fourth quarter and full year 2025 earnings report, scheduled for November 21, 2025, is eagerly anticipated. This report will offer further clarity on the company's financial health and its potential for future growth. With key figures like President and CEO John Marotta and CFO Lawrence Lin leading the charge, Azenta is well-positioned to continue its trajectory in the life sciences sector. The consistent price target set by analysts, particularly the bullish outlook from Evercore ISI, underscores the confidence in Azenta's strategic direction and operational success.

Published on: November 20, 2025